Wedbush analyst Laura Chico raised the firm’s price target on Travere Therapeutics (TVTX) to $44 from $39 and keeps an Outperform rating on the shares. The firm notes the Food and Drug Administration granted full approval for Travere’s sNDA for Filspari in focal segmental glomerulosclerosis. While the label restricts usage in FSGS patients with active nephrotic syndrome, this still encompasses about 30k U.S. FSGS patients and has no limitations for FSGS types. With no other FSGS therapies approved, Wedbush anticipates physicians and patients will be eager to adopt Filspari. The firm projects Q4 Filspari FSGS revenue to reach $26M.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics up 43% in premarket at $43.81 on FDA approval for Filspari
- Travere Therapeutics price target raised to $54 from $49 at Guggenheim
- Ligand price target raised to $250 from $244 at BofA
- Travere Therapeutics price target raised to $49 from $44 at BofA
- Travere Therapeutics price target raised to $56 from $47 at Canaccord